Skip to main content

Table 2 Univariate and multivariate analysis of prognostic factors in patients with (PFS)

From: Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience

Parameters

Median (months)

95% CI

P

value

Hazard ratio

95% CI

P

value

Age

  

.821

–

  

≦65 (n = 74)

3.8

2.7–4.9

    

  > 65 (n = 44)

3.3

2.3–4.2

    

Gender

  

.540

–

  

 Male (n = 58)

2.8

2.2–3.4

    

 Female (n = 60)

4.0

2.8–5.3

    

ICD-10 cancer site

  

.011

   

 C22.1 – ICCA (n = 86)

3.9

2.6–5.2

 

0.877

0.321–2.397

.799

 C23/C24.9 –GB/others (n = 18)

2.7

2.4–3.0

 

1.568

0.510–4.819

.433

 C24.0 – ECCA (n = 9)

8.0

0.0–24.4

 

1

  

 C24.1 – Ampullary (n = 5)

3.3

1.7–4.8

 

1.519

0.378–6.110

.556

Performance status

  

.260

–

  

 0/1 (n = 102)

3.8

2.7–4.9

    

 2/3 (n = 16)

2.7

1.8–3.7

    

NLR

  

.020

   

≦7.45 (n = 100)

3.8

2.8–4.8

 

1

  

  > 7.45 (n = 18)

2.4

1.4–3.3

 

1.982

1.040–3.777

.038

MLR

  

.028

   

≦0.28 (n = 40)

5.9

4.3–7.4

 

1

  

  > 0.28 (n = 78)

2.9

2.5–3.3

 

1.263

0.737–2.162

.396

PLR

  

.396

–

  

≦136.4 (n = 47)

4.8

2.9–6.8

    

  > 136.4 (n = 71)

3.1

2.7–3.5

    

Albumin (g/dL)

  

.777

–

  

≦3.5 (n = 33)

3.1

2.6–3.6

    

  > 3.5 (n = 72)

3.9

2.8–4.9

    

ALT (U/L)

  

.484

–

  

≦36 (n = 68)

3.2

2.3–4.0

    

  > 36 (n = 49)

4.3

2.8–5.7

    

Bilirubin (mg/dL)

  

.622

–

  

≦1.3 (n = 89)

3.8

2.6–5.0

    

  > 1.3 (n = 28)

3.3

2.4–4.1

    

ALP (U/L)

  

.060

–

  

≦94 (n = 30)

5.9

2.5–9.2

    

  > 94 (n = 82)

2.8

2.4–3.3

    

Creatinine (mg/dL)

  

.612

–

  

≦1.27 (n = 115)

3.6

2.6–4.6

    

  > 1.27 (n = 3)

2.7

0.0–6.7

    

CA19–9 (U/mL)

  

.263

–

  

≦37 (n = 35)

2.9

2.3–3.4

    

  > 37 (n = 82)

4.3

2.7–5.9

    

CEA (ng/mL)

  

.347

–

  

≦5 (n = 64)

4.3

3.0–5.7

    

  > 5 (n = 54)

3.2

2.7–3.6

    

Biliary drainage

  

.047

   

 None (n = 88)

3.2

2.4–4.0

 

1.396

0.497–3.921

.527

 Internal drainage(n = 8)

7.6

3.2–12.1

 

1

  

 PTCD (n = 19)

3.4

2.8–4.0

 

0.711

0.244–2.066

.531

 Both (n = 3)

1.3

0.5–2.1

 

8.710

1.831–41.445

.007

Tumor involvement

 Primary tumor

  

.081

–

  

  No (n = 8)

2.6

2.1–3.1

    

  Yes (n = 110)

3.8

2.7–4.8

    

 Regional LAP

  

.679

–

  

  No (n = 42)

3.9

2.6–5.1

    

  Yes (n = 76)

3.2

2.3–4.1

    

 Lung

  

<.001

   

  No (n = 95)

4.3

3.0–5.6

 

1

  

  Yes (n = 23)

2.6

2.2–3.1

 

1.678

0.905–3.112

.101

 Bone

  

.181

   

  No (n = 105)

3.8

2.7–4.8

    

  Yes (n = 13)

3.4

2.3–4.5

    

 Liver

  

.034

   

  No (n = 69)

4.3

2.2–6.3

 

1

  

  Yes (n = 49)

3.2

2.1–4.2

 

1.232

0.759–1.998

.398

 Peritoneum

  

.138

–

  

  No (n = 96)

3.9

2.5–5.2

    

  Yes (n = 22)

3.1

2.5–3.7

    

 Distant LAP

  

.785

–

  

  No (n = 102)

3.4

2.3–4.5

    

  Yes (n = 16)

3.6

2.5–4.7

    

 Tumor Response

  

<.0001

   

  CR/RR (n = 15)

14.1

7.9–20.2

 

1

  

  SD (n = 41)

7.6

6.4–8.8

 

1.819

0.824–4.015

.139

  PD (n = 48)

2.5

2.4–2.7

 

55.556

19.467–158.550

<.0001

  N/A (n = 14)

1.3

0.8–1.9

 

63.905

20.396–200.232

<.0001

  1. CI Confidence interval, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, N/A Not assessed, ALP Alkaline phosphatase, ALT Alanine aminotransferase, NLR Neutrophil to lymphocyte ratio, MLR Monocyte to lymphocyte ratio, PLR Platelet to lymphocyte ratio, LAP Lymphadenopathy, PTCD Percutaneous transhepatic cholangiography drainage, ICCA Intrahepatic cholangiocarcinoma, ECCA Extrahepatic cholangiocarcinoma, GB Gallbladder
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us